Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Director | June 01, 2026 | June 03, 2026 |
| INVE Technologies, Inc.INVE · Entity 7037 | Director | July 30, 2026 | August 03, 2026 |
| Medtronic plcMDT · Entity 2888 | SVP & Chief Medical & Science | November 05, 2021 | November 09, 2021 |
| Rockley Photonics Holdings LtdRKLY · Entity 122956 | Director | August 08, 2022 | August 31, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2036-06-01 | Direct | 40,412 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 40,412 · Balance 40,412 F1: Scheduled to vest in four equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: Scheduled to vest in four equal quarterly installments.
INVE Technologies, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,712 |
Reported balance
After 2026-07-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-30 · Grant · Acquired 17,544 · Balance 65,712 F1: Restricted Stock Units granted pursuant to Issuer's 2011 Incentive Compensation Plan vesting 1/12th monthly beginning the vesting commencement date of June 1, 2026. Vested shares will be delivered to the reporting person on the earlier of (i) three years from the initial vesting start date of the award or (ii) the separation of service. F2: Includes an aggregate of 16,082 shares of common stock issuable pursuant to restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units granted pursuant to Issuer's 2011 Incentive Compensation Plan vesting 1/12th monthly beginning the vesting commencement date of June 1, 2026. Vested shares will be delivered to the reporting person on the earlier of (i) three years from the initial vesting start date of the award or (ii) the separation of service.
F2: Includes an aggregate of 16,082 shares of common stock issuable pursuant to restricted stock units that have not vested.
Medtronic plc
Report date November 05, 2021 · Filed November 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 74,945 |
Reported balance
After 2021-11-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-11-05 · Tax withholding · Disposed 209 · Balance 74,945 F1: This balance increased by 239 shares due to exempt transactions such as dividend reinvestment. F2: The reported transaction involved the withholding of 209 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible. |
Filing footnotes · ownership attribution and instrument terms
F1: This balance increased by 239 shares due to exempt transactions such as dividend reinvestment.
F2: The reported transaction involved the withholding of 209 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible.
Rockley Photonics Holdings Ltd
Report date August 08, 2022 · Filed August 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 60,837 |
Reported balance
After 2022-08-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-08 · Grant · Acquired 60,837 · Balance 60,837 F1: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ZimVie Inc.
Report date October 20, 2025 · Filed October 20, 2025
Section 16 reporting ended · disclosed 2025-10-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-20 · Disposition to issuer · Disposed 13,072.965 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated July 20, 2025, by and among the Issuer, Zamboni Parent Inc., a Delaware corporation ("Parent"), and Zamboni MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on October 20, 2025 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the Effective Time, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), reported on this Form 4 was converted into the right to receive $19.00 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F2: At the Effective Time, each deferred share unit (whether settled in cash or in shares of Common Stock, including any such deferred stock unit resulting from the reinvestment of dividend equivalents) (each, a "Deferred Share Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Deferred Share Unit immediately prior to the Effective Time and (ii) the Merger Consideration. F4: As required by the terms of the Merger Agreement, the Issuer accelerated the vesting, as of immediately prior to the Effective Time, contingent upon the closing of the transactions contemplated by the Merger Agreement, of all of the outstanding and unvested equity awards held by Dr. Kuntz. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-20 · Disposition to issuer · Disposed 57,728 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated July 20, 2025, by and among the Issuer, Zamboni Parent Inc., a Delaware corporation ("Parent"), and Zamboni MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on October 20, 2025 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the Effective Time, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), reported on this Form 4 was converted into the right to receive $19.00 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3: At the Effective Time, each restricted stock unit with respect to Common Stock (each, a "Restricted Stock Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. Each Restricted Stock Unit represented a contingent right to receive one share of Common Stock. F4: As required by the terms of the Merger Agreement, the Issuer accelerated the vesting, as of immediately prior to the Effective Time, contingent upon the closing of the transactions contemplated by the Merger Agreement, of all of the outstanding and unvested equity awards held by Dr. Kuntz. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated July 20, 2025, by and among the Issuer, Zamboni Parent Inc., a Delaware corporation ("Parent"), and Zamboni MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on October 20, 2025 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the Effective Time, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), reported on this Form 4 was converted into the right to receive $19.00 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F2: At the Effective Time, each deferred share unit (whether settled in cash or in shares of Common Stock, including any such deferred stock unit resulting from the reinvestment of dividend equivalents) (each, a "Deferred Share Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Deferred Share Unit immediately prior to the Effective Time and (ii) the Merger Consideration.
F3: At the Effective Time, each restricted stock unit with respect to Common Stock (each, a "Restricted Stock Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. Each Restricted Stock Unit represented a contingent right to receive one share of Common Stock.
F4: As required by the terms of the Merger Agreement, the Issuer accelerated the vesting, as of immediately prior to the Effective Time, contingent upon the closing of the transactions contemplated by the Merger Agreement, of all of the outstanding and unvested equity awards held by Dr. Kuntz.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 24, 2019 Filed Dec 26, 2019 22:36 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,808 | $0.00 Strike: $55.32 | $0.00 |
DisclosureSEC source: 0001127602-19-035863 · form4.xml · derivative · entry 10 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,808 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option to purchase 1,808 New Medtronic ordinary shares for $55.32 per share, which was partially vested at the effective time of the Merger, was received in the Merger and represents the conversion of 1,808 Medtronic common stock shares for $55.32 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 22:36 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,404 | $0.00 Strike: $41.60 | $0.00 |
DisclosureSEC source: 0001127602-19-035863 · form4.xml · derivative · entry 9 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,404 shares Expires 2022-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 2,404 New Medtronic ordinary shares for $41.60 per share, which was partially vested at the effective time of the Merger, was received in the Merger and represents the conversion of 2,404 Medtronic common stock shares for $41.60 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 22:36 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 38,558 | $113.56 | $4,378,646.48 |
DisclosureSEC source: 0001127602-19-035863 · form4.xml · nonDerivative · entry 8 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,013 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $113.48 to $113.66, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes to this Form 4. F1 · balance_after: This balance increased by 283 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 22:36 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 38,558 | $55.32 | $2,133,028.56 |
DisclosureSEC source: 0001127602-19-035863 · form4.xml · nonDerivative · entry 7 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance increased by 283 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 22:36 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 1,808 | $113.66 | $205,497.28 |
DisclosureSEC source: 0001127602-19-035863 · form4.xml · nonDerivative · entry 6 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,013 F1 · balance_after: This balance increased by 283 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 22:36 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 1,808 | $55.32 | $100,018.56 |
DisclosureSEC source: 0001127602-19-035863 · form4.xml · nonDerivative · entry 5 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance increased by 283 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 22:36 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 2,404 | $113.60 | $273,094.40 |
DisclosureSEC source: 0001127602-19-035863 · form4.xml · nonDerivative · entry 4 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,013 F1 · balance_after: This balance increased by 283 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 22:36 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 2,404 | $41.60 | $100,006.40 |
DisclosureSEC source: 0001127602-19-035863 · form4.xml · nonDerivative · entry 3 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance increased by 283 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 22:36 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 3,019 | $113.63 | $343,048.97 |
DisclosureSEC source: 0001127602-19-035863 · form4.xml · nonDerivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,013 F1 · balance_after: This balance increased by 283 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 22:36 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 5,067 | $113.64 | $575,813.88 |
DisclosureSEC source: 0001127602-19-035863 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,032 F1 · balance_after: This balance increased by 283 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| September 27, 2019 Filed Sep 30, 2019 21:52 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 100 | $108.21 | $10,821.00 |
DisclosureSEC source: 0001127602-19-029262 · form4.xml · nonDerivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,816 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 27, 2019 Filed Sep 30, 2019 21:52 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 21,325 | $107.51 | $2,292,672.08 |
DisclosureSEC source: 0001127602-19-029262 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,916 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.02 to $107.95, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2019 Filed Aug 2, 2019 22:29 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 5,719 | $102.02 | $583,452.38 |
DisclosureSEC source: 0001127602-19-025932 · form4.xml · nonDerivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,241 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 22:29 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 4,795 | $102.37 | $490,864.15 |
DisclosureSEC source: 0001127602-19-025932 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,960 Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:56 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025555 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:56 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 68,901 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025555 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,901 Underlying: Ordinary Shares · 68,901 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:56 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 10,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025555 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,755 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 298 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 22, 2019 Filed Jul 23, 2019 22:03 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 3,438 | $101.12 | $347,650.56 |
DisclosureSEC source: 0001127602-19-025080 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,127 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: This balance increased by 324 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| March 20, 2019 Filed Mar 29, 2019 21:11 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-013603 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,241 F1 · security: This balance increased by 616 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| March 20, 2019 Filed Jun 12, 2019 22:09 UTC Amendment | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-021490 · form4a.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,241 F1 · security: This balance increased by 616 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 20:38 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 41,227 | $0.00 Strike: $38.81 | $0.00 |
DisclosureSEC source: 0001127602-18-026464 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 41,227 shares Expires 2022-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option to purchase 41,227 New Medtronic ordinary shares for $38.81 per share, which was partially vested at the effective time of the Merger, was received in the Merger and represents the conversion of 41,227 Medtronic common stock shares for $38.81 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 20:38 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 47,176 | $95.88 | $4,523,088.63 |
DisclosureSEC source: 0001127602-18-026464 · form4.xml · nonDerivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,403 F1 · price: The price is a weighted average price. These shares were sold in multiple transactions in prices ranging from $95.82 to $95.9850, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote in this Form 4. Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 20:38 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 41,227 | $38.81 | $1,600,019.87 |
DisclosureSEC source: 0001127602-18-026464 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 20:34 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 4,987 | $90.48 | $451,223.76 |
DisclosureSEC source: 0001127602-18-024847 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,352 Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:49 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 1,695 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024242 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: Ordinary Shares · 1,695 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:49 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 61,004 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024242 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,004 Underlying: Ordinary Shares · 61,004 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:49 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 10,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024242 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,339 F1 · security: This balance increased by 312 shares due to exempt transactions such as dividend reinvestment. F2 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 20:36 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 11,500 | $87.13 | $1,001,995.00 |
DisclosureSEC source: 0001127602-18-020614 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,923 F1 · price: The price is a weighted average price. These shares were sold in multiple transactions in prices ranging from $87.09 to $87.155, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote in this Form 4. F2 · balance_after: This balance increased by 316 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 22:40 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,872 | $0.00 Strike: $34.88 | $0.00 |
DisclosureSEC source: 0001127602-18-001566 · form4.xml · derivative · entry 5 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 45,872 shares Expires 2021-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option to purchase 45,872 New Medtronic ordinary shares for $34.88 per share, which was partially vested at the effective time of the Merger, was received in the Merger and represents the conversion of 45,872 Medtronic common stock shares for $34.88 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 22:40 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,492 | $0.00 Strike: $37.53 | $0.00 |
DisclosureSEC source: 0001127602-18-001566 · form4.xml · derivative · entry 4 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 35,492 shares Expires 2020-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 35,492 New Medtronic ordinary shares for $37.53 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 35,492 Medtronic common stock shares for $37.53 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 22:40 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 78,526 | $86.21 | $6,769,726.46 |
DisclosureSEC source: 0001127602-18-001566 · form4.xml · nonDerivative · entry 3 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,107 F1 · security: This balance increased by 324 shares due to exempt transactions such as dividend reinvestment. F2 · price: The price reported in Column 4 is a weighted Average price. The shares were sold in multiple transactions at prices ranging from $86.12 to $86.26, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes to this Form 4. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 22:40 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 45,872 | $34.88 | $1,600,015.36 |
DisclosureSEC source: 0001127602-18-001566 · form4.xml · nonDerivative · entry 2 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 22:40 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 35,492 | $37.53 | $1,332,014.76 |
DisclosureSEC source: 0001127602-18-001566 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:05 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 1,191 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024715 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191 Underlying: Ordinary Shares · 1,191 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:05 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 41,285 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024715 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,285 Underlying: Ordinary Shares · 41,285 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:05 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 10,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024715 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,945 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:43 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 4,621 | $84.29 | $389,504.09 |
DisclosureSEC source: 0001127602-17-024470 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,623 F1 · balance_after: This balance increased by 1159 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| September 27, 2016 Filed Sep 28, 2016 20:25 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 17,141 | $86.70 | $1,486,056.14 |
DisclosureSEC source: 0001127602-16-063340 · form4.xml · nonDerivative · entry 3 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,085 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.675 to $86.725, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 20:25 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,624 | $0.00 Strike: $35.92 | $0.00 |
DisclosureSEC source: 0001127602-16-063340 · form4.xml · derivative · entry 4 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,624 shares Expires 2019-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 30,624 New Medtronic ordinary shares for $35.92 per share, which was fully vested at the effective time of the Merger, was received in the Merger and represents the conversion of 30,624 Medtronic common stock shares for $35.92 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 20:25 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 25,199 | $86.67 | $2,183,997.33 |
DisclosureSEC source: 0001127602-16-063340 · form4.xml · nonDerivative · entry 2 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,226 F1 · price: The price is a weighted average price. These shares were sold in multiple transactions in prices ranging from $86.57 to $86.735, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote in this Form 4. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 20:25 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 30,624 | $35.92 | $1,100,014.08 |
DisclosureSEC source: 0001127602-16-063340 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SrVP & Chief Scien, Clin, Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.